Kymera Therapeutics (KYMR) Return on Sales (2019 - 2025)
Historic Return on Sales for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to 33.51%.
- Kymera Therapeutics' Return on Sales fell 142100.0% to 33.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 1397.46%, marking a year-over-year increase of 13997500.0%. This contributed to the annual value of 84.48% for FY2024, which is 823700.0% down from last year.
- Kymera Therapeutics' Return on Sales amounted to 33.51% in Q3 2025, which was down 142100.0% from 7.38% recorded in Q2 2025.
- Over the past 5 years, Kymera Therapeutics' Return on Sales peaked at 2.21% during Q4 2024, and registered a low of 33.51% during Q3 2025.
- In the last 5 years, Kymera Therapeutics' Return on Sales had a median value of 3.37% in 2025 and averaged 5.74%.
- As far as peak fluctuations go, Kymera Therapeutics' Return on Sales soared by 29900bps in 2021, and later tumbled by -142100bps in 2025.
- Kymera Therapeutics' Return on Sales (Quarter) stood at 2.23% in 2021, then fell by -8bps to 2.4% in 2022, then soared by 83bps to 0.4% in 2023, then surged by 646bps to 2.21% in 2024, then tumbled by -1617bps to 33.51% in 2025.
- Its Return on Sales was 33.51% in Q3 2025, compared to 7.38% in Q2 2025 and 3.37% in Q1 2025.